123I-vasoactive intestinal peptide (VIP) receptor scanning: Update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tract

Nuclear Medicine and Biology

Volumn 23, Issue 6, 1996, Pages 685-692

  Virgolini, I ^a   Raderer, M ^a   Kurtaran, A ^a   Angelberger, P ^b   Yang, Q ^a   Radosavljevic, M ^a   Leimer, M ^a   Kaserer, K ^a   Li, S R ^a   Kornek, G ^a   Hubsch P ^a   Niederle, B ^a   Pidlich, J ^c   Scheithauer, W ^a   Valent, P ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b ARC SEIBERSDORF RESEARCH GMBH   (Austria)

^c NONE

Author keywords

adenocarcinoma; endocrine tumor; gastrointestinal tract; receptor scanning; vasoactive intestinal peptide

Indexed keywords

IODINE 123; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR; DIAGNOSTIC AGENT; RADIOACTIVE IODINE;

ADULT; AGED; CANCER SCINTISCANNING; CONFERENCE PAPER; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; ENDOCRINE TUMOR; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; METASTASIS; ADENOCARCINOMA; AMINO ACID SEQUENCE; ANIMAL; ARTICLE; CELL STRAIN COS1; GASTROINTESTINAL TUMOR; METABOLISM; MOLECULAR GENETICS; RADIOASSAY; SCINTISCANNING; ULTRASTRUCTURE;

ADENOCARCINOMA; AMINO ACID SEQUENCE; ANIMALS; COS CELLS; ENDOCRINE GLAND NEOPLASMS; GASTROINTESTINAL NEOPLASMS; HUMANS; IODINE RADIOISOTOPES; MOLECULAR SEQUENCE DATA; RADIOLIGAND ASSAY; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; VASOACTIVE INTESTINAL PEPTIDE;

EID: 0030204115     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/0969-8051(96)00066-2     Document Type: Conference Paper

References (44)

1. 1. Battari A., Martin J. M., Luis J., Pouzol O., Secchi J., Marvaldi J. and Pichon J. (1988) Solubilization of the vasoactive intestinal peptide receptor from human colonic adenocarcinoma cells. J. Biol. Chem. 263, 17685-17689.
2. 2. Bloom S. R., Polak J. M. and Pearse A. G. E. (1973) Vasoactive intestinal peptide and watery diarrhea, syndrome. Lancet ii, 14-16.
3. 3. Brazeau P., Vale W., Burgus R., Ling N., Butcher M., Livier J. and Guellemin R. (1973) Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 119, 77-79.
4. 4. Cohn J. (1987) Vasoactive intestinal peptide stimulates protein phosphorylation in a colonic epithelial cell line. Am. J. Physiol. 16, G420-G424.
5. 5. Corness J. D., Demchyshyn L. L. and Seeman P. (1993) A human somatostatin receptor (SSTR3), located on chromosome 22, displays preferential affinity for somatostatin-14-like peptides. FEBS 321, 279-284.
6. 6. Couvineau A. and Laburthe M. (1985) The human vasoactive intestinal peptide receptor: Molecular identification by covalent cross-linking in colonic epithelium. J. Clin. Endocrinol. Metab. 61, 50-55.
7. 7. Couvineau A., Amiranoff B. and Laburthe M. (1986) Solubilization of the liver vasoactive intestinal peptide receptors. J. Biol. Chem. 261, 14482-14489.
8. 8. Couvineau A., Voisin T., Guijarro L. and Laburthe M. (1990) Purification of vasoactive intestinal peptide receptor from porcine liver by a newly designed one-step affinity chromatography. J. Biol. Chem. 265, 13386-13390.
9. 9. Couvineau A., Rouyer-Fessard C., Darmoul D., Maotet J. J., Carrero I. Ogier-Denis E. and Laburthe M. (1994) Human intestinal VIP receptor: Cloning and functional expression of two cDNA encoding proteins with different N-terminal domains. Biochem. Biophys. Res. Commun. 200, 769-776.
10. 10. Demchyschyn L. L., Srikant C. B., Sunahara R. K., Kent G., Seeman P., Tol van H. H., Panetta R., Patel Y. C. and Niznik H. B. (1993) Cloning and expression of a human somatostatin-14-selective receptor variant (somatostatin receptor 4) located on chromosome 20. Mol. Pharmacol. 43, 894-901.
11. 11. Gespach C., Bawab W., de Cremoux P. and Calvo F. (1988) Pharmacology, molecular identification and functional characteristics of vasoactive intestinal peptide receptors in human breast cancer. Cancer Res. 48, 5079-5083.
12. 12. Gozes I. and Brenneman D. E. (1989) VIP: Molecular biology and neurobiological function. Mol. Neurobiol. 3, 201-236.
13. 13. Inagaki N., Yoshida N., Mizuta M., Mizuno N., Fujii Y., Gonoi T., Miyazaki J. I. and Seino S. (1994) Cloning and functional characterization of a third pituitary adenylate cyclase-activating polypeptide subtype expressed in insulin-secreting cells. Proc. Natl. Acad. Sci. USA 91, 2679-2683.
14. 111In-DTPA-D-Phe-1-)-octreotide: A case history. Ann. N.Y. Acad. Sci. 733, 496-506.
15. 15. Krenning E. P., Bakker W. H., Breeman W. A. P., Koper J. W., Kooij P. P. M., Ausema L., Lamberts J. S. and Reubi J. C. (1989) Localization of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet i, 242-244.
16. 123I-Tyr-3-octreotide: The Rotterdam experience with more than 1000 patients. Eur. J. Nucl. Med. 20, 716-731.
17. 123I-vasoactive intestinal peptide (VIP) in the localization diagnosis of medullary thyroid carcinoma (MTC). Nucl. Med. Biol. 23, 503-507.
18. 18. Kvols L. K., Moertel C. G., O'Connell M. J., Schutt A. J., Rubin J. and Hahn R. G. (1986) Treatment of the malignant carcinoid syndrome. N. Engl. J. Med. 315, 663-666.
19. 19. Laburthe M. and Couvineau A. (1988) Molecular analysis of vasoactive intestinal peptid receptors: A comparison with receptors for VIP-related peptides: In: Vasoactive Intestinal Peptide and Related Peptides (Edited by Said S. and Mutt V.), Vol. 527, pp. 296-313. New York Academy of Sciences, New York.
20. 20. Lamberts S. W. J., Bakker W. H., Reubi J. C. and Krenning E. P. (1990) Somatostatin-receptor imaging in the localization of endocrine tumors. N. Engl. J. Med. 323, 1246-1249.
21. 21. Lutz E. M., Sheward W. J., West K. M., Fink G. and Harmar A. J. (1993) The VIP2 receptor: Molecular characterization of a cDNA encoding a novel receptor for vasoactive intestinal peptide. FEBS Lett. 334, 3-8.
22. 22. Maton P. N. (moderator) (1989) Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann. Int. Med. 110, 353-364.
23. 23. Pincus D. W., DiCicco-Bloom E. M. and Black I. B. (1990) Vasoactive intestinal polypeptide regulates mitosis, differentiation and survival of cultured sympathetic neuroblasts. Nature 343, 564-567.
24. 24. Reichlin S. (1983) Somatostatin. N. Engl. J. Med. 309, 1556-1563.
25. 25. Reubi A. C. (1995) In vitro identification of vasoactive intestinal peptide receptors in human tumors: Implications for tumor imaging. J. Nucl. Med. 36, 1846-1853.
26. 26. Robberecht P., de Neef P., Gourlet P., Cauvin A., Coy, D. H. and Christophe J. (1989) Pharmacological characterization of the novel helodermin/VIP receptor present in human SUP-T1 lymphoma cell membranes. Regul. Pept. 26, 117-126.
27. 27. Rohrer L., Raulf F., Bruns C., Buetter R., Hofstaedter F. and Schüle R. (1993) Cloning and characterization of a fourth human somatostatin receptor. Proc. Natl. Acad. Sci. U.S.A. 90, 4196-4200.
28. 28. Said S. I. and Mutt V. (1970) Polypeptide with broad biological activity: Isolation from small intestine. Science 169, 1217-1218.
29. 29. Said S. I. and Faloona G. R. (1975) Elevated plasma and tissue levels of vasoactive intestinal peptide in the watery diarrhea syndrome. N. Engl. J. Med. 293, 155-158.
30. 30. Scatchard G. (1949) The attractions of proteins for small molecules and ions. Ann. N.Y. Acad. Sci. 51, 660-672.
31. 31. Silverberg E., Boring C. E. and Squires T. S. (1990) Cancer statistics, 1990. Ca. 40, 9-26.
32. 32. Sreedharan S. P., Robichon A., Peterson K. E. and Goetzl E. J. (1993) Cloning and expression of the human vasoactive intestinal peptide receptor. Proc. Natl. Acad. Sci. U.S.A. 88, 4986-4990.
33. 33. Svoboda M., Tastenoy M., van Rampelbergh J., Goosens J. F., De Neef P., Waelbroeck M. and Robberecht P. (1994) Molecular cloning and functional characterization of a human VIP receptor from sup-T1 lymphoblasts. Biochem. Biophys. Res. Commun. 205, 1617-1624.
34. 34. Verner J. V. and Morrison A. B. (1958) Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia. Am. J. Med. 25, 374-380.
35. 1 binding capacity. Br. J. Cancer 61, 937-941.
36. 2 receptor. J. Biol. Chem. 267, 12700-12708.
37. 37. Virgolini I., Yang Q., Li S. R., Angelberger P., Neuhold N., Niederle B., Scheithauer W. and Valent P. (1994a) Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors. Cancer Res. 54, 690-700.
38. 123I-Labeled vasoactive intestinal peptide (VIP) for the localization of intestinal adenocarcinomas and endocrine tumors. N. Engl. J. Med. 331, 1116-1121.
39. 39. Virgolini I., Kurtaran A., Raderer M., Angelberger P., Niederle B. and Valent P. (1995) Vasoactive intestinal peptide receptor scintigraphy. J. Nucl. Med. 36, 1732-1739.
40. 40. Wagener D. J., de Mulder P. H. and Wils J. A. (1994) Multimodality treatment of locally advanced pancreatic cancer. Ann. Oncol. 3, 81-86.
41. 41. Yamada Y., Post S. R., Wang K., Tager H. S., Bell G. I. and Seino S. (1992a) Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc. Natl. Acad. Sci. U.S.A. 89, 251-255.
42. 42. Yamada Y., Reisine T., Law S. F., Ihara Y., Kubota A., Kagimoto S., Seino M., Seino Y., Bell G. I. and Seino S. (1992b) Somatostatin receptors, an expanding gene family: Cloning and functional characterization of human SSTR3, a protein coupled to adenylyl cyclase. Mol. Endocrinol. 6, 2136-2142.
43. 43. Yamada Y., Kagimoto S., Yasuda K., Masuda K., Someya Y., Ihara Y., Li Q., Imura H. and Seino S. (1993) Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and fifth (hSSTR5) human somatostatin receptor subtype. Biochem. Biophys. Res. Commun. 195, 844-852.
44. 44. Yasuda K., Res-Domiano S., Breder C. A., Law S. F., Saper C., Reisine, T. and Bell G.I. (1992) Cloning of a novel somatostatin receptor, SST3, coupled to adenylate cyclase. J. Biol. Chem. 267, 20422-20428.